Price$1.79-0.03 (-1.65%)
04:00 PM07:45 PM
News · 26 weeks54-67%
2026-04-192026-10-11
Mix2790d
- SEC Filings15(56%)
- Other12(44%)
Latest news
25 items- SECSEC Form EFFECT filed by Can-Fite Biopharma LtdEFFECT - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form EFFECT filed by Can-Fite Biopharma LtdEFFECT - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 424B3 filed by Can-Fite Biopharma Ltd424B3 - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form F-3 filed by Can-Fite Biopharma LtdF-3 - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECAmendment: SEC Form F-3/A filed by Can-Fite Biopharma LtdF-3/A - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form EFFECT filed by Can-Fite Biopharma LtdEFFECT - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form EFFECT filed by Can-Fite Biopharma LtdEFFECT - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form D filed by Can-Fite Biopharma LtdD - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver TransplantationPatient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the publication of a peer-reviewed case report describing the clinical course of a patient with advanced decompensated liver cirrhosis treated with Namodenoson. During treatment, the patient experienced resolution of ascites and regression of esophageal
- SECSEC Form POS AM filed by Can-Fite Biopharma LtdPOS AM - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form POS AM filed by Can-Fite Biopharma LtdPOS AM - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer StudyRAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for H1 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes. The open-label Phase IIa study enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed following standard therapies. Fourteen pa
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross ProceedsRAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise price of $5.00 per ADS, issued by Can-Fite in March 2026, at a reduced exercise price of $2.50 per ADS. The ADSs representing ordinary shares issuable upon exercise of the warrants are registered pursuant t
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer StudyCompany plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced that blinded overall survival observed across the entire patient population in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma (HCC) appears longer than originally anticipated based on the assumptions underlying the study design. The pivotal Phase III study is a randomiz
- SECSEC Form F-3 filed by Can-Fite Biopharma LtdF-3 - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic CancerThe New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer. The findings provide mechanistic support for the design of Can-Fite’s planned Phase IIb study evaluating namodenoson in combination with gemcitabine and additional standard-of-c
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
- PRCan-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug CandidatesNamodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today provided an update on the regulatory status of its two lead drug candidates, Piclidenoson and Namodenoson. Both drug candidates are being advanced in Phase III clinical development programs under regulatory frameworks established with the U.S. Food and Drug Administration (FDA) and the European
- SECSEC Form 6-K filed by Can-Fite Biopharma Ltd6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
CANF FAQ
6 questionsWhat does Can-Fite Biopharma Ltd do?
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, COVID-19 and erectile dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic...Where does CANF stock trade?
Can-Fite Biopharma Ltd (CANF) is listed on AMEX.What sector and industry is CANF in?
Can-Fite Biopharma Ltd operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CANF?
Can-Fite Biopharma Ltd has had 2 recent analyst actions on file. The most recent action was from D. Boral Capital: Buy with a $700.00 price target on 2026-05-13. Recent price targets range from $500.00 to $700.00.What companies are similar to CANF?
Notable peers in the same industry include RCUS (Arcus Biosciences Inc.), ITOS (iTeos Therapeutics Inc.), CRVS (Corvus Pharmaceuticals Inc.). Compare CANF side-by-side with any of them on Quantisnow.How can I track CANF on Quantisnow?
Quantisnow aggregates Can-Fite Biopharma Ltd's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CANF to receive live email and push alerts on every new disclosure.